Last reviewed · How we verify
9MW0311
9MW0311 is a monoclonal antibody targeting PD-L1 to enhance anti-tumor immune responses by blocking the interaction between PD-L1 and PD-1/B7-1.
9MW0311 is a monoclonal antibody targeting PD-L1 to enhance anti-tumor immune responses by blocking the interaction between PD-L1 and PD-1/B7-1. Used for Non-small cell lung cancer, Other solid tumors (under investigation in phase 3).
At a glance
| Generic name | 9MW0311 |
|---|---|
| Sponsor | Mabwell (Shanghai) Bioscience Co., Ltd. |
| Drug class | PD-L1 inhibitor |
| Target | PD-L1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
9MW0311 binds to programmed death ligand 1 (PD-L1) on tumor cells and immune cells, preventing its interaction with PD-1 and B7-1 receptors on T cells. This blockade reverses T cell exhaustion and restores anti-tumor immunity, allowing the immune system to recognize and eliminate cancer cells more effectively.
Approved indications
- Non-small cell lung cancer
- Other solid tumors (under investigation in phase 3)
Common side effects
- Fatigue
- Decreased appetite
- Immune-related adverse events (pneumonitis, hepatitis, colitis)
- Infusion-related reactions
Key clinical trials
- A Study on Efficacy, Safety and Immunogenicity of 9MW0311 in Postmenopausal Women With Osteoporosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 9MW0311 CI brief — competitive landscape report
- 9MW0311 updates RSS · CI watch RSS
- Mabwell (Shanghai) Bioscience Co., Ltd. portfolio CI